Novel hederagenin-triazolyl derivatives as potential anti-cancer agents

Eur J Med Chem. 2016 Jun 10:115:257-67. doi: 10.1016/j.ejmech.2016.03.018. Epub 2016 Mar 9.

Abstract

A series of novel aryl-1H-1,2,3-triazol-4-yl methylester and amide derivatives of the natural product hederagenin was synthesized aiming to develop new antitumor agents, using Huisgen 1,3-dipolar cycloaddition reactions, with yields between 35% and 95%. The structures of all derivatives (2-31) were confirmed by MS, IR, (1)H NMR and (13)C NMR spectroscopic data. The cytotoxic activities of all compounds were screened against a panel of six human cancer cell lines using SRB assay. It was found that most of the compounds displayed higher levels of antitumor activities as compared to parent hederagenin. Compounds 4, 8 and 15 were the most potent against all human cancer cell lines. Furthermore, compound 11 was the most cytotoxic against cell HT29 showing EC50 = 1.6 μM and a selectivity index of 5.4.

Keywords: Hederagenin derivatives; Huisgen 1,3-dipolar cycloaddition; SRB assay; Sapindus saponaria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Line, Tumor
  • Drug Screening Assays, Antitumor
  • Humans
  • Oleanolic Acid / analogs & derivatives*
  • Oleanolic Acid / chemistry
  • Triazoles / chemistry*

Substances

  • Antineoplastic Agents
  • Triazoles
  • Oleanolic Acid
  • hederagenin